摘要
目的探讨艾迪莎对溃疡性结肠炎(UC)患者血清白介素8(IL8)的调节作用及作用机制。方法60例UC患者随机分为两组:A组30例和B组30例。A组采用艾迪莎治疗,B组采用柳氮磺胺吡啶治疗。采用双抗体夹心法ELISA法测定两组患者治疗前后和30例健康志愿者血清IL8的水平。结果A组显效率为80.0%(24/30),B组显效率为53.3%(16/30),两组比较,有显著性差异(P<0.05)。A组治疗后血清IL8水平与对照组比较无显著性差异(P>0.05),B组治疗后血清IL8水平仍高于对照组(P<0.05)。结论艾迪莎治疗UC疗效显著,能够下调IL8的表达及生成,可能是其治疗UC的作用机制之一。
Objective To investigate the regulatory effects of Etiasa on IL-8 in patients with ulcerative colitis(UC),and to further elucidate its therapeutic mechanism.Methods Thirty patients with UC as treatment group and thirty health persons as control group underwent the testing. The serum of all testing persons were taken pre-and post-treatment to detect IL-8 by ELISA.Results Effects of Etiasa were obviously better than SASP,and could down-regulate serum level of IL-8 of the patients with ulcerative colitis to normal level,but SASP could not.Conclusion Etiasa has distinct therapeutic effects on UC by down-regulating the expression of IL-8.
出处
《江西医学院学报》
2005年第3期73-75,共3页
Acta Academiae Medicinae Jiangxi